文献速递慢阻肺间质性肺疾病肺结节与肺癌

肺癌、慢阻肺与特发性肺纤维化患者临终医疗与姑息治疗使用差异比较

Differences in Health Care and Palliative Care Use at the End of Life: A Comparison Study Among Lung Cancer, COPD, and Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Chest · 2024-08-24

本研究回顾性纳入加州大学旧金山分校1819例生命最后6个月内至少一次门诊就诊的肺癌、慢阻肺或特发性肺纤维化(IPF) deceased患者,比较其临终医疗与姑息治疗使用。以肺癌为参照,慢阻肺和IPF患者接受门诊姑息治疗和门诊阿片类处方的调整比值比更低,而临终ICU使用调整比值比更高;IPF患者住院姑息治疗调整比值比更高。

要点

  • 慢阻肺和IPF患者门诊姑息治疗及阿片类处方使用低于肺癌患者。
  • 慢阻肺和IPF患者临终ICU使用高于肺癌患者。
  • IPF患者住院姑息治疗使用高于肺癌患者。

核心结论

  • 与肺癌患者相比,慢阻肺和IPF患者接受门诊姑息治疗和阿片类处方的可能性更低,而临终ICU使用可能性更高。

研究设计与样本

  • 回顾性研究,纳入1819例在加州大学旧金山分校生命最后6个月内至少有一次门诊就诊的肺癌、慢阻肺或IPF deceased患者。
  • 采用多因素logistic回归计算各结局的调整比值比(aOR),以肺癌为参照组。

主要发现

  • 与肺癌患者相比,慢阻肺患者接受门诊姑息治疗的aOR为0.26(95%CI 0.19-0.36),IPF患者为0.48(95%CI 0.32-0.70),P < .001。
  • 与肺癌患者相比,慢阻肺患者接受门诊阿片类处方的aOR为0.50(95%CI 0.40-0.63),IPF患者为0.40(95%CI 0.29-0.54)。
  • 与肺癌患者相比,慢阻肺患者临终ICU使用的aOR为2.88(95%CI 2.11-3.93),IPF患者为4.15(95%CI 2.66-6.49)。
  • IPF患者接受住院姑息治疗的aOR为2.02(95%CI 1.30-3.13),P = .002。

临床怎么用

  • 在呼吸科终末期慢阻肺和IPF患者管理中,应关注门诊姑息治疗和阿片类处方的可及性,并评估临终ICU使用偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with lung cancer, idiopathic pulmonary fibrosis (IPF), and COPD have high symptom burden, poor quality of life, and high health care use at the end of life. Although proactive integration of palliative care in lung cancer can improve outcomes, it is unclear whether similar practices have been adopted in COPD and IPF care. RESEARCH QUESTION: Do patients with COPD and IPF have different patterns of health care and palliative care use at the end of life compared with patients with lung cancer? STUDY DESIGN AND METHODS: We retrospectively identified deceased patients with lung cancer, COPD, or IPF with ≥ 1 outpatient visit at the University of California, San Francisco, in the last 6 months of life. We compared outpatient palliative care and opioid prescriptions, inpatient palliative care, hospitalizations, intensive care use, and in-hospital death in the last 6 months of life between each group. We used multivariable logistic regression to calculate adjusted ORs (aORs) of each outcome, with lung cancer as the reference group. RESULTS: Among 1,819 patients, patients with COPD and IPF were more likely to be male and older at the time of death compared with patients with lung cancer. Compared with patients with lung cancer, patients with COPD and IPF showed a lower adjusted odds (P < .001) of receiving outpatient palliative care (COPD: aOR, 0.26 [95% CI, 0.19-0.36]; IPF: aOR, 0.48 [95% CI, 0.32-0.70]), outpatient opioid prescription (COPD: aOR, 0.50 [95% CI, 0.40-0.63]; IPF: aOR, 0.40 [95% CI, 0.29-0.54]), and a higher odds of end-of-life ICU use (COPD: aOR, 2.88 [95% CI, 2.11-3.93]; IPF: aOR, 4.15 [95% CI, 2.66-6.49]). Patients with IPF showed higher odds of receiving inpatient palliative care (aOR: 2.02 [95% CI, 1.30-3.13]; P = .002). INTERPRETATION: This study showed that patients with COPD and IPF are less likely to receive outpatient palliative care and opioid prescriptions and are more likely to use end-of-life intensive care than patients with lung cancer. Further research should explore health system barriers contributing to differences in care patterns to optimize quality of life and to align with patient goals of care.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Suen AO, Bischoff K, Iyer AS, et al. Differences in Health Care and Palliative Care Use at the End of Life: A Comparison Study Among Lung Cancer, COPD, and Idiopathic Pulmonary Fibrosis. Chest. 2024. PMID: 39186972. doi:10.1016/j.chest.2024.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。